NDA 216834 · Ucb INC
Zilbrysq
Zilucoplan Sodium · Subcutaneous
NovelOrphanCDER novel approval, Oct 17, 2023: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 17, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
18
10 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 15, 2026 Supplement 15 · Efficacy OrphanLetterLabelMedication Guide
- Oct 17, 2023 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
3 products under this application
- ZILBRYSQ · ZILUCOPLAN SODIUM EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZILBRYSQ · ZILUCOPLAN SODIUM EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ZILBRYSQ · ZILUCOPLAN SODIUM EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zilucoplan" as an intervention, any sponsor and status, largest first.
- HEALEY ALS Platform Trial - Master ProtocolPivotal-lookingActive, not recruiting
Merit E. Cudkowicz, MDAcademic, hospital or other
NCT04297683 · 1,500 participants (planned) · Start Jun 14, 2020 · Primary completion Jul 2027
Drug: Zilucoplan; Verdiperstat and 6 more · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 81 sites in all
- Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized PatientsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT04590586 · 515 participants · Start Nov 24, 2020 · Primary completion Aug 3, 2021
Drug: Standard of care; Apremilast and 5 more · For: COVID-19
Sites: Anniston, Alabama; Bakersfield, California; Chula Vista, California · 59 sites in all
- Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisPivotal-lookingCompleted
NCT04225871 · 200 participants · Start Dec 23, 2019 · Primary completion Jul 31, 2026
Drug: zilucoplan (RA101495) · For: Generalized Myasthenia Gravis
Sites: Mobile, Alabama; Phoenix, Arizona; Irvine, California · 70 sites in all
- Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisPivotal-lookingCompleted
Ra Pharmaceuticals, Inc.Industry
NCT04115293 · 174 participants · Start Sep 17, 2019 · Primary completion Dec 30, 2021
Drug: zilucoplan (RA101495); Placebo · For: Myasthenia Gravis, Generalized
Sites: Mobile, Alabama; Phoenix, Arizona; Los Angeles, California · 77 sites in all
- HEALEY ALS Platform Trial - Regimen A ZilucoplanPivotal-lookingCompleted
Merit E. Cudkowicz, MDAcademic, hospital or other
NCT04436497 · 162 participants · Start Jul 29, 2020 · Primary completion Apr 13, 2022
Drug: Zilucoplan; Matching Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Boston, Massachusetts
University Hospital, GhentAcademic, hospital or other
NCT04382755 · 81 participants · Start May 22, 2020 · Primary completion Dec 29, 2020
Drug: Zilucoplan®; Placebo · For: COVID-19
Sites: Aalst, Belgium; Bruges, Belgium; Brussels, Belgium · 9 sites in all
Ra PharmaceuticalsIndustry
NCT03315130 · 45 participants · Start Oct 11, 2017 · Primary completion Dec 10, 2018
Drug: zilucoplan (RA101495); Placebo · For: Generalized Myasthenia Gravis
Sites: Mobile, Alabama; Carlsbad, California; Los Angeles, California · 30 sites in all
- A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia GravisPivotal-lookingCompleted
NCT06471361 · 31 participants · Start Aug 27, 2024 · Primary completion Jan 28, 2025
Drug: Zilucoplan · For: Generalized Myasthenia Gravis
Sites: New Haven, Connecticut; Tampa, Florida; Columbia, Missouri · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zilbrysq (Zilucoplan Sodium)
2024 spending
$37.1M
Beneficiaries
202
966 claims
Per beneficiary
$183,754
$1,871.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $37,118,311 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF, Bresch S, Genge A, et al. · Lancet Neurol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.
Saccà F, Pane C, Espinosa PE, et al. · Eur J Neurol 2023 · Systematic Review, Network Meta-Analysis
- Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.
Hewamadduma C, Freimer M, Genge A, et al. · J Neurol 2025 · Clinical Trial, Phase III, Multicenter Study
- Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
Howard JF, Nowak RJ, Wolfe GI, et al. · JAMA Neurol 2020 · Clinical Trial, Phase II, Multicenter Study
- Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.
Smith AG, Wolfe GI, Habib AA, et al. · Adv Ther 2024 · Comparative Study, Network Meta-Analysis
- Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj AG, Lehtinen AE, Forsyth C, et al. · Haematologica 2024 · Clinical Trial, Phase II, Letter
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.